Horizon Pharma plc Provides Update on Relationship With Specialty Pharmacies

DUBLIN, IRELAND -- (Marketwired) -- 10/21/15 -- Horizon Pharma plc (NASDAQ: HZNP), a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs, today provided an update on its relationship with specialty pharmacies:

• Horizon primary care and specialty medicines are distributed by both specialty and retail pharmacies.
• All pharmacies that distribute Horizon branded medicines are fully independent. Horizon does not own or have an ownership stake in any pharmacy and does not possess an option to purchase any pharmacy. In addition, the relationship with these pharmacies is non-exclusive where each of these pharmacies may also fulfill prescriptions for other drug manufacturers.
• Consistent with most pharmaceutical companies, Horizon sells medicines to wholesalers and receives sales proceeds from the wholesaler. Horizon does not own or have any ownership stake in any drug wholesaler nor does Horizon possess an option to purchase any wholesaler.

About Horizon Pharma plc Horizon Pharma plc is a biopharmaceutical company focused on improving patients' lives by identifying, developing, acquiring and commercializing differentiated and accessible medicines that address unmet medical needs. The Company markets seven medicines through its orphan, primary care and specialty business units. Horizon's global headquarters are in Dublin, Ireland. For more information, please visit www.horizonpharma.com. Follow @HZNPplc on Twitter or view careers on our LinkedIn page.

Contacts:

Investors:
John Thomas
Executive Vice President, Strategy and Investor Relations
[email protected]

Tina Ventura
Vice President, Investor Relations
[email protected]

U.S. Media Contact:
Geoff Curtis
Group Vice President, Corporate Communications
[email protected]

Ireland Media Contact:
Ray Gordon
Gordon MRM
[email protected]

Source: Horizon Pharma plc

You May Also Be Interested In

• Greenberg Traurig Advises SL Green on $312.2M Sale of Midtown Manhattan Office Property
• TEAMSTERS, ALLIES RELEASE REPORT ON AMAZON VIOLATIONS OF NEW YORK WARN ACT
• Investor Relations and Fundraising Strategist Liana Zavo Brings “Shark Tank on Steroids” Roadshow Model to New York City and Global Markets